Press Room

2021 CPhI Japan

Start
Wednesday, April 14, 2021 - 00:00
End
Friday, April 30, 2021 - 00:00
Location: Osaka, Japan
Drug Product Dry Granulation | Hovione

If you are attending CPhI Japan and would like to chat with us about your challenges, schedule a meeting with us. Yasushi Usuda will be pleased to meet you.

With more than 25 years’ experience in Inhalation, Hovione is your solution partner from early proof-of-concept to commercial scale manufacture.

yasushi-usuda-photo

Yasushi Usuda

Director of Japan Office

 

 

CPhI Japanに出展するホビオンをご覧ください。また、今から面談をご予約しませんか。

​​​​​Visit Hovione at CPhI Japan Connect and schedule a meeting.

 

 

Webinar (available in English)

Title: “Leveraging Particle Engineering towards the Delivery of Biopharmaceuticals”

Date/ Time: April 15th, 2:00 pm JST

 

Watch On-Demand Webinar

(Restricted content)

 

Biopharmaceuticals represent the most promising and fastest-growing field in the pharmaceutical area. These therapeutics show very high specificity and potency at relatively low concentrations and enable the treatment of otherwise untreatable diseases.

 

 

What can you learn from this webinar?

  • Formulation screening for biologics
  • Spray drying of monoclonal antibodies
  • Spray freeze drying
  • Pulmonary Delivery of enzymes
  • A series of case-studies will also be shown for each of the relevant technologies.

     

Speakers:

Paulo Lino, PhD - Scientist, R&D Drug Product Development

João Sá, PhD - Scientist, R&D Drug Product Development

 

 

Watch On-Demand Webinar

(Restricted content)

 

Our experts are available to address all challenges, helping your projects to succeed.

 

Schedule a meeting button | Hovione



 



 



 



 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026